The majority of patients recover from a COVID-19 infection without permanent impairment, but a significant proportion suffer from long-term consequences even after the infection has subsided, known as Post-COVID syndrome. To date, there is no approved therapy and only the various symptoms are treated. The "RAPID_REVIVE" study is now being conducted as part of the NUM research project NAPKON-TIP. It is investigating whether drug treatment with a drug that has not yet been approved has a positive effect on Post-COVID syndrome. To this end, the new medication is being compared with a placebo as part of the study. The study is being conducted at 11 locations across Germany. Patients aged 18 and over with persistent symptoms of Post-COVID syndrome can take part.
Further participation requirements and information on the study